How Shayk Is Expanding Access to FDA-Aligned Hormone Therapy for Women
Hormone therapy for women is undergoing a meaningful shift, shaped by updated regulatory guidance, rising demand, and a growing expectation that healthcare should be more accessible.
For years, treatment decisions around hormone therapy were influenced by broad safety warnings that came out of early interpretations of large-scale studies in the early 2000s. Those warnings created a cautious environment where many women either delayed treatment or avoided it entirely, despite experiencing symptoms that significantly affected their quality of life.
That landscape changed in late 2025. The FDA began removing long-standing boxed warnings from many hormone therapy medications, reflecting a more updated understanding of risk based on years of additional research. Rather than applying generalized caution to all women, the agency now emphasizes individualized decision-making based on factors such as age, timing of menopause, medical history, and overall health.
This shift has helped reshape conversations between patients and healthcare providers. More women are now seeking treatment for symptoms tied to hormonal changes, including hot flashes, night sweats, disrupted sleep, mood instability, brain fog, vaginal dryness, and fatigue. At the same time, healthcare systems are adjusting to meet this increased demand, creating opportunities for new models of care that improve both access and continuity.
Shayk is part of a growing group of telehealth platforms working to close that gap. The platform focuses specifically on women’s hormone therapy and simplifies access into a more structured process. Patients begin with a short intake, followed by provider review that typically happens within the same or next day. If treatment is appropriate, prescriptions are issued and delivered directly to the patient’s home, eliminating many of the delays associated with traditional office visits.
Speed is one part of the model, but it is not the defining feature. The more significant shift is how Shayk approaches continuity of care. Hormone therapy is rarely a one-time decision. As symptoms change and women respond differently to treatment, medications and dosages often need to be adjusted over time. Rather than treating therapy as a fixed prescription, Shayk is designed around ongoing communication between patients and providers.
Patients are able to message their provider directly and typically receive responses within a day. Questions about symptoms, medication adjustments, or side effects can often be addressed without waiting weeks for another appointment. That ongoing relationship allows treatment plans to evolve based on patient feedback instead of remaining static.
This approach aligns with what current clinical guidance suggests. Hormone therapy works best when it is tailored and monitored over time. A personalized treatment plan combined with regular follow-up can help providers optimize care while responding to changes in symptoms or patient needs.
Another defining aspect of Shayk‘s model is its use of FDA-approved medications only. In a rapidly expanding market, where different types of hormone formulations are available through a variety of providers, this creates a clear standard. By focusing on FDA-approved therapies, Shayk emphasizes treatments that have been reviewed for safety, quality, and effectiveness while remaining aligned with evolving regulatory guidance.
Pricing is also structured transparently, with both monthly and longer-term options available. The model reduces uncertainty and allows patients to understand costs before beginning treatment, helping women make informed decisions without unexpected expenses.
At the same time, supply challenges remain across the industry. Increased demand following updated FDA guidance has placed pressure on certain medications, particularly estrogen patches. These shortages have highlighted the importance of having multiple treatment pathways and consistent provider oversight. When one formulation becomes difficult to obtain, providers may need to recommend an alternative while continuing to monitor patient outcomes.
Shayk addresses this by offering different forms of therapy while maintaining a unified care model. Patients continue working with the same provider, allowing treatment to remain consistent even if medication options need to change because of supply availability or individual response.
As awareness continues to grow and barriers to access continue to fall, hormone therapy is becoming a more central part of women’s healthcare. More women are seeking evidence-based information and personalized treatment rather than accepting disruptive symptoms as an inevitable part of aging.
Digital health platforms are helping make that transition possible by reducing wait times, expanding access to qualified providers, and supporting long-term care instead of one-time prescriptions.
Platforms that combine accessibility, clinical structure, transparency, and continuity are likely to define the next phase of this category. As hormone therapy continues to evolve, patients increasingly expect care that is convenient, personalized, and grounded in current clinical evidence.
By combining streamlined access with ongoing provider relationships and FDA-approved treatment options, Shayk reflects the broader direction of women’s hormone therapy, one that prioritizes individualized care while making treatment more accessible for women seeking support throughout perimenopause and menopause.
